Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was upgraded by analysts at The Goldman Sachs Group from a "hold" rating to a "strong-buy" rating in a research note issued to investors on Thursday,Zacks.com reports.
Other equities analysts also recently issued research reports about the stock. Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft to a "hold" rating in a report on Monday, April 28th. Wall Street Zen upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Friday.
Check Out Our Latest Stock Analysis on BAYRY
Bayer Aktiengesellschaft Stock Performance
Shares of Bayer Aktiengesellschaft stock opened at $7.59 on Thursday. The company has a market capitalization of $29.83 billion, a PE ratio of -29.19 and a beta of 0.84. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32. The company has a 50-day simple moving average of $6.45 and a two-hundred day simple moving average of $5.86. Bayer Aktiengesellschaft has a one year low of $4.79 and a one year high of $8.58.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported $0.65 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.02. The business had revenue of $15.27 billion during the quarter, compared to the consensus estimate of $13.39 billion. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. Research analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.
About Bayer Aktiengesellschaft
(
Get Free Report)
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bayer Aktiengesellschaft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list.
While Bayer Aktiengesellschaft currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
